Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. AON
8. TMUS
9. ALHC
10. LBRX

Go back to Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c

Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

February 28, 2017 7:00 AM EST

RICHMOND, Calif., Feb. 28, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2016 financial results and recent accomplishments.

"Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy," said Sandy Macrae, CEO of Sangamo. "With our recently expanded capabilities in clinical... More